Albert Berghuis
Professor
Microbiology & Immunology
McGill University
Canada
Biography
McGill Life Sciences Complex, Bellini Pavillion
Research Interest
Structure-based Drug Design is a scientific approach towards drug discovery. The approach involves examining the detailed structure of a protein—often an enzyme—whose (mal-)functioning is responsible for a disease. This information can be used to design compounds that specifically interact with that protein, thereby correcting its functioning. Such compounds are, in principal, drugs against the disease. The Berghuis Lab uses X-ray crystallography to obtain detailed structural information of proteins and is subsequently using this information for Structure-based Drug Design efforts. We are targeting bacterial and fungal infections, and antibiotic resistance.
Publications
-
Structural Basis for Kinase-Mediated Macrolide Antibiotic Resistance. Fong DH, Burk DL, Blanchet J, Yan AY, Berghuis AM.
-
Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A,
-
Effect of solvent and protein dynamics in ligand recognition and inhibition of aminoglycoside adenyltransferase 2″-Ia. Bacot-Davis VR, Bassenden AV, Sprules T, Berghuis AM.
